Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrintยฎ as the only commercially Read More